12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyrica CR pregabalin controlled-release: Phase III data

Top-line data from 121 evaluable patients in the double-blind portion of an international Phase III trial showed that once-daily 300-495 mg pregabalin CR met the primary endpoint of improving median time to LTR, defined as a reduction in pain of <30% relative to mean baseline pain or withdrawal, at week 13 vs. placebo (58 vs. 22 days p=0.021). LTR occurred in 54% of patients receiving pregabalin CR vs. 70.7% for placebo. Pregabalin CR was well tolerated with dizziness, somnolence, peripheral edema, insomnia, headache, fatigue,...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >